Literature DB >> 2581259

Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

M E Medof, T Kinoshita, R Silber, V Nussenzweig.   

Abstract

Purified decay-accelerating factor (DAF), from the stroma of normal human erythrocytes, was incorporated into the membranes of erythrocytes of patients with paroxysmal nocturnal hemoglobinuria (PNH), and its effect on the complement sensitivity of the cells was investigated. Reconstitution with exogenous DAF restored the ability of the affected PNH cells to resist assembly of the homologous C3 convertase, C4b2a, on their surfaces, and decreased the susceptibility of the cells to lysis in acidified serum. Conversely, treatment of normal erythrocytes with monoclonal or polyclonal anti-DAF antibodies abrogated the capacity of the normal cells to circumvent C4b2a assembly and rendered the cells sensitive to acid lysis. These findings show that the previously reported association of DAF deficiency with PNH is causally related to the lytic abnormalities of the cells and clarify the molecular basis for restriction of autologous convertase formation on normal human erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581259      PMCID: PMC397690          DOI: 10.1073/pnas.82.9.2980

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; C M Soldato; W F Rosse
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

2.  Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; P J Baker; W F Rosse
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

3.  Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.

Authors:  V W Hu; M L Shin
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

4.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

5.  Increased sensitivity to complement of erythroid and myeloid progenitors in paroxysmal nocturnal hemoglobinuria.

Authors:  E N Dessypris; D A Clark; L C McKee; S B Krantz
Journal:  N Engl J Med       Date:  1983-09-22       Impact factor: 91.245

6.  Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.

Authors:  E J Brown; J Ramsey; C H Hammer; M M Frank
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

7.  Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

8.  Two populations of erythroid cell progenitors in paroxysmal nocturnal hemoglobinuria.

Authors:  B Rotoli; R Robledo; N Scarpato; L Luzzatto
Journal:  Blood       Date:  1984-10       Impact factor: 22.113

Review 9.  Paroxysmal nocturnal haemoglobinuria.

Authors:  W F Rosse; C J Parker
Journal:  Clin Haematol       Date:  1985-02

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  38 in total

1.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 2.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 5.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

6.  Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.

Authors:  H A Stafford; M L Tykocinski; D M Lublin; V M Holers; W F Rosse; J P Atkinson; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

7.  Solution structure of a functionally active fragment of decay-accelerating factor.

Authors:  Stanislava Uhrinova; Feng Lin; Graeme Ball; Krystyna Bromek; Dusan Uhrin; M Edward Medof; Paul N Barlow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

8.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L R Fredrick; N J Bernshaw; L A Wilcox; C J Parker
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

9.  Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.

Authors:  Saifur R Ahmad; Elaine A Lidington; Rieko Ohta; Noriko Okada; Michael G Robson; Kevin A Davies; Michael Leitges; Claire L Harris; Dorian O Haskard; Justin C Mason
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.